Healthcare
Live Price
Offline$6.11
+0.00% today
1Y Change
-15.84%
Window
Jun 23, 2025 → Jun 17, 2026
Coverage: 248 bars · Jun 23, 2025 → Jun 17, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Ryman Healthcare Limited (RYHTY) is a Healthcare stock with a market cap of $2.20B and listed on OTC. The stock last traded around $6.11 and down 15.8% across the available one-year price window (Jun 23, 2025 → Jun 17, 2026). Baseline metrics include revenue growth of +9.7%, EPS growth of -8940.6%, a dividend yield of 0.0%. What stands out right now is revenue +9.7%, EPS -8940.6%, free cash flow -37.7% with operating margin -8.1% and ROIC -0.5%. Valuation is more restrained than many high-expectation growth names at price/sales 2.9. Overall, the current profile looks closer to a turnaround or cyclical reset than a generic broad-market placeholder. Stock Foundry combines RYHTY price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Benchmark Comparison
Compare this ticker against a broad index, growth benchmark, or sector ETF using a shared 1Y normalization window.
RYHTY
—
Normalized return
SPY
—
S&P 500
Excess Return
—
Relative to SPY
RYHTY Max Drawdown
-28.99%
Trailing 1Y
SPY Max Drawdown
—
Trailing 1Y
Uses the longest available daily history for RYHTY and SPY.
Financial profile
Profitability, balance sheet stamina, and cash efficiency drawn from the latest filings.
FY Revenue
$452.4M
-10.2% YoY
FY Net Income
$423.1M
-38.9% YoY
Free Cash Flow
$147.1M
-38.0% YoY
Revenue Growth
+9.7%
EPS Growth
-8940.6%
Gross Margin
-8.1%
Net Margin
-75.9%
Income statement
NZD
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | 714M | 651M | 560M | 504M | 452M |
| Gross Profit | 714M | -1M | -20M | 2M | 25M |
| Operating Income | -118M | -70M | -20M | 2M | 25M |
| EBITDA | -27M | -51M | 458M | 788M | 462M |
| Net Income | -437M | 5M | 258M | 693M | 423M |
| EPS (Diluted) | — | — | — | — | — |
Balance sheet
NZD
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Cash & Equivalents | 18M | 42M | 28M | 28M | 20M |
| Total Assets | 12.1B | 13.1B | 12.5B | 11.0B | 9.2B |
| Total Liabilities | 7.8B | 8.7B | 7.8B | 7.5B | 6.3B |
| Shareholder Equity | 4.3B | 4.4B | 4.7B | 3.4B | 2.8B |
| Total Debt | 1.7B | 2.6B | 2.3B | 2.6B | 2.3B |
| Net Debt | 1.7B | 2.5B | 2.3B | 2.6B | 2.3B |
Cash flow positioning
Latest Full Year
Operating Cash Flow
376M
-29.9% YoY
Capital Expenditures
229M
+23.4% YoY
Free Cash Flow
147M
-38.0% YoY
Key ratios
Gross Margin
-8.1%
Operating Margin
-8.1%
Net Margin
-75.9%
ROE
-13.7%
Debt / Equity
0.40x
Next Step
Use the numbers to decide whether this is a growth candidate, a quality compounder, or just an interesting outlier.